Tasly Pharmaceutical Group Co., Ltd.

Jingyan Han

Jun Guo

Mingxia Wang

Yuying Liu

Jiying Yang

Yu Zhang

Kai Sun

Yu Xuan Zhang

The present invention relates to a new use of traditional Chinese drug products of Danshensu (DLA), Notoginsenoside R1 (R1) and their combination, in particular to the therapeutic and preventive effects of DLA, R1 and their combination on the diseases caused by microcirculation disorder.

Use of Danshensu, Notoginsenoside R1 or their combination in preparation of medicaments for preventing and treating diseases caused by microcirculation disorder

The present invention discloses a traditional Chinese drug consisting of Danshen extract and Sanqi extract, the pharmaceutical composition comprising the above traditional Chinese drug as an active component and the use thereof. The traditional Chinese drug consists of Danshen extract and Sanqi extract in a weight ratio of (2&#x2dc;6):(0.5&#x2dc;2). The invention further discloses the effect of the above traditional Chinese drug and the pharmaceutical composition comprising the above traditional Chinese drug as an active component for treating cardiac microcirculation disorder and myocardial damage induced by ischemia/reperfusion.

Traditional Chinese drug comprising Danshen extracts and Sanqi extracts and use thereof

Growing community of inventors

Tianjin, China

Jingyan Han